Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis.

ABSTRACT: Inhaled therapies allow for the targeted delivery of antimicrobials directly into the lungs and have been widely used in the treatment of cystic fibrosis (CF) acute pulmonary exacerbations. Nebulized levofloxacin solution (MP-376) is a novel therapy that is currently being evaluated in phase I, II, and III clinical trials among patients with stable CF and recent isolation of Pseudomonas aeruginosa from sputum. Phase I studies have investigated the single and multiple-dose pharmacokinetics of MP-376 and shown that it is rapidly absorbed from the lungs and results in low systemic concentrations. A subsequent phase IB study found that MP-376 pharmacokinetics were comparable among adults and children 6-16 years of age. Further phase II studies reported that sputum P. aeruginosa density decreas

SUBMITTER: Stockmann C 

PROVIDER: S-EPMC5564390 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature